Amyotrophic Lateral Sclerosis Patients Have an Alternative to Radicava ORS via IV
qimono / Pixabay

Amyotrophic Lateral Sclerosis Patients Have an Alternative to Radicava ORS via IV

The new FDA-approved oral formulation of  Radicava ORS (edaravone) is more convenient than the intravenous formulation, yet the efficacy and composition remain the same. The oral formulation may also be…

Continue Reading Amyotrophic Lateral Sclerosis Patients Have an Alternative to Radicava ORS via IV
May is Amyotrophic Lateral Sclerosis Awareness Month: Spreading Rare Disease Awareness
source: pixabay.com

May is Amyotrophic Lateral Sclerosis Awareness Month: Spreading Rare Disease Awareness

According to a story from ALS News Today, around 5,000 people get diagnosed with amyotrophic lateral sclerosis (ALS) annually. In addition, costs of treatment for patients average $250,000 out of…

Continue Reading May is Amyotrophic Lateral Sclerosis Awareness Month: Spreading Rare Disease Awareness
The House Passes a New Act Which Will Accelerate Research for ALS and Related Diseases
source: pixabay.com

The House Passes a New Act Which Will Accelerate Research for ALS and Related Diseases

Three organizations focused on amytrophic lateral sclerosis (ALS) as well as other rare neurodegenerative diseases, have just celebrated the House of Representatives' passage of the ACT for ALS (H.R.3537/S.1813). The…

Continue Reading The House Passes a New Act Which Will Accelerate Research for ALS and Related Diseases

Study of the Week: Study Reveals a Key Mechanism of Neurodegenerative Diseases

Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…

Continue Reading Study of the Week: Study Reveals a Key Mechanism of Neurodegenerative Diseases
Newly FDA Approved Ketamine Has the Potential to Slow ALS Progression
qimono / Pixabay

Newly FDA Approved Ketamine Has the Potential to Slow ALS Progression

An October 2021 report published in the Globe and Newswire carried an announcement by Fabio Chianelli, CEO of the biotech company PharmaTher Holdings. The FDA approved orphan drug status for…

Continue Reading Newly FDA Approved Ketamine Has the Potential to Slow ALS Progression
Is There a Right or Wrong in the Debate Between Patients and Manufacturers to Release Drugs Through Compassionate Use?
source: pixabay.com

Is There a Right or Wrong in the Debate Between Patients and Manufacturers to Release Drugs Through Compassionate Use?

  Following several Patient Worthy articles on the subject earlier this year, Fierce Biotech recently published news that Biogen is preparing to release the Phase III VALOR trial drug, tofersen,…

Continue Reading Is There a Right or Wrong in the Debate Between Patients and Manufacturers to Release Drugs Through Compassionate Use?
New Hope for ALS and Friedreich’s Ataxia Patients Through Viral Vector Transports
mcmurryjulie / Pixabay

New Hope for ALS and Friedreich’s Ataxia Patients Through Viral Vector Transports

A recent announcement in Biospace by Capsida Biotherapeutics and CRISPR Therapeutics of their newly-formed partnership offers renewed hope for amyotrophic lateral sclerosis (ALS) and Friedreich’s Ataxia patients. The companies believe…

Continue Reading New Hope for ALS and Friedreich’s Ataxia Patients Through Viral Vector Transports